Completion of the treatment period of a dasotraline core study (ie, SEP360 221) for the treatment of BED
Subject has agreed to participate by providing written informed consent and is willing and able to comply with the protocol, in the opinion of the investigator
Subject has not taken any medication other than the study drug for the purpose of controlling BED symptoms during the core study
Female subject must have a negative urine pregnancy test at open label (OL) Baseline; females who are post-menopausal (defined as at least 12 months of spontaneous amenorrhea) and those who have undergone hysterectomy or bilateral oophorectomy will be exempted from the pregnancy test
Female subject of childbearing potential and male subject with female partner of childbearing potential must agree to use an effective and medically acceptable form of birth control (see Section 22, Appendix III) throughout the study period. Note: Continued use of an effective and medically acceptable form of birth control is recommended for 30 days after study completion
Subject is judged by the investigator to be suitable for participation in a 12 month clinical trial involving open-label dasotraline treatment
Subject can read well enough to understand the informed consent form and other subject materials
Subject is considered by the investigator to be at imminent risk of suicide, injury to self or to others, or damage to property
Subject answers "yes" to "suicidal ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C SSRS assessment at OL Baseline. Subjects who answer "yes" to this question must be referred to the Investigator for follow up evaluation
Subject has a clinically significant abnormality including physical examination, vital signs, ECG, or laboratory tests that the investigator in consultation with the medical monitor considers to be inappropriate to allow participation in the study
Subject has a positive urine drug screen (UDS) or breath alcohol test at OL Baseline
Subject is breastfeeding
Subject is at high risk of non-compliance in the investigator's opinion
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.